STOCK TITAN

Tango Therapeutics (TNGX) director receives 4,000 RSUs and 25,000-share option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics director John B. Ketchum received an equity grant consisting of 4,000 restricted stock units and an option for 25,000 shares of Common Stock. The RSUs vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, subject to continued service. The stock option, with a $20.22 exercise price, vests in 12 equal monthly installments beginning July 5, 2026 and expires on June 5, 2036. Following these grants, Ketchum directly holds 24,937 shares of Common Stock.

Positive

  • None.

Negative

  • None.
Insider Ketchum John B
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 25,000 $0.00 --
Grant/Award Common Stock 4,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 25,000 shares (Direct, null); Common Stock — 24,937 shares (Direct, null)
Footnotes (1)
  1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
RSU grant 4,000 shares Restricted stock units granted to director on June 5, 2026
Stock option grant size 25,000 shares Option covering Common Stock granted on June 5, 2026
Option exercise price $20.22/share Exercise price for 25,000-share stock option
Option expiration June 5, 2036 Expiration date of stock option grant
Vesting start for option July 5, 2026 First monthly vesting date for the stock option
Shares held after grant 24,937 shares Non-derivative Common Stock directly held after transactions
restricted stock units financial
"These shares are represented by restricted stock units (the "RSUs")."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Each RSU represents a contingent right to receive one share of Common Stock."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for 25,000.0000 shares."
vest financial
"The RSUs will vest in their entirety on the earlier of June 5, 2027 or the next annual meeting."
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price financial
"conversion_or_exercise_price: "20.2200" for the stock option grant."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ketchum John B

(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.,
201 BROOKLINE AVE., SUITE 901

(Street)
BOSTON MASSACHUSETTS 02215

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A4,000(1)A$024,937D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$20.2206/05/2026A25,000 (2)06/05/2036Common Stock25,000$025,000D
Explanation of Responses:
1. These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in their entirety on the earlier of: (i) June 5, 2027 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
2. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Remarks:
Exhibit 24: Power of Attorney
/s/ Julie Fogarty, as attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tango Therapeutics (TNGX) director John B. Ketchum receive in this Form 4 filing?

John B. Ketchum received equity compensation, including 4,000 restricted stock units and a stock option for 25,000 shares. These awards are part of his compensation as a director and are subject to multi-year vesting and service-based conditions.

How do the 4,000 restricted stock units for TNGX director Ketchum vest?

The 4,000 RSUs vest in full on the earlier of June 5, 2027 or the date of the next annual stockholder meeting. Vesting is contingent on Ketchum’s continuous service with Tango Therapeutics through the applicable vesting date.

What are the key terms of John B. Ketchum’s 25,000-share stock option at Tango Therapeutics (TNGX)?

Ketchum’s option covers 25,000 shares of Common Stock with a $20.22 exercise price. It vests in 12 substantially equal monthly installments starting July 5, 2026 and expires on June 5, 2036, assuming continuous service during the vesting period.

How many Tango Therapeutics (TNGX) shares does Ketchum hold after these equity grants?

After the reported grant of 4,000 RSU-linked shares, Ketchum directly holds 24,937 shares of Tango Therapeutics Common Stock. This figure reflects his direct non-derivative holdings immediately following the latest reported transaction on June 5, 2026.

Are Ketchum’s Tango Therapeutics (TNGX) equity awards open-market purchases or compensation grants?

The reported transactions are compensation-related grants, not open-market purchases. Both the 4,000 RSUs and the 25,000-share stock option were awarded at a $0.00 grant price under a grant or award code, subject to vesting and service conditions.